In-vivo Bioequivalence Study of Ozanimod 0.92 mg Capsulesof The Test Drug (Torenzo 0.92 mg Caps., Abidi Pharma, Iran)

Authors
Category Primary study
Registry of TrialsIranian Registry of Clinical Trials
Year 2024
This article has no abstract
Epistemonikos ID: bae3295c6c0bc1169a2f97847e7cf3e16884aba0
First added on: Apr 11, 2025